London · Delayed Price · Currency is GBP · Price in GBX Ondine Biomedical Earnings Call Transcripts
Fiscal Year 2026
-
The LANTERN Phase 3 study met its primary endpoint, showing a 40.5% reduction in 30-day surgical site infections with nasal photodisinfection added to standard care, supported by robust Bayesian and frequentist analyses. The intervention demonstrated a strong safety profile and broad-spectrum efficacy, with rapid hospital payback and significant global market potential.
Fiscal Year 2025
-
Revenue grew 29% to CAD 2.6M, driven by new hospital deployments and increased utilization, while R&D spend surged to support a pivotal phase III trial nearing readout. Manufacturing scale-up and commercial expansion are underway, with FDA submission targeted for the fall.
-
Strong revenue and margin growth were achieved in H1 2025, with expanding adoption in Canada, the UK, and Europe. Strategic partnerships and a robust product pipeline support future growth, while recent funding secures operations through Q2 2026.
Fiscal Year 2024
-
2024 saw 70% revenue growth, improved gross margins, and expanded hospital adoption, driven by new partnerships and product launches. Cash runway extends into early Q4 2025, with key clinical studies progressing and strategic funding secured.
-
Revenue doubled year-over-year, driven by rapid hospital adoption and a major partnership with Mölnlycke. The company is launching a pivotal US phase 3 trial and expanding into ICU indications, while maintaining strong margins and operational efficiency.
Fiscal Year 2023
-
Revenues nearly doubled in 2023 with exponential hospital adoption and improved gross margins. U.S. phase III study is set for 2024, with commercialization expected in 2026, while international growth and operational scaling continue.